Featured Suppliers:

Commonwealth Biotechnologies Incorporated

News from Zibb.com

StockProfiler.US: HearAtLast Holdings, Inc. & Commonwealth Biotechnologies, Inc. - Zibb.com

New York, NY,, Oct 23, 2009 (M2 PRESSWIRE via COMTEX) --

HearAtLast Holdings, Inc. (PINKSHEETS: HRAL); Commonwealth Biotechnologies, Inc. (NASDAQ: CBTE)

Stock Profiler welcomes investors to sign up at www.stockprofiler.us. to subscribe to our FREE newsletter. Please follow our thread on www.twitter.com at StockProfilerUS

Stock Profiler is pleased to introduce HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) to the investment community. Please visit us at www.stockprofiler.us for more detailed information.

-------------------------------------------

HearAtLast Holdings, Inc. closed at $0.047 Thursday, trading 55,900 shares.

Company News- October 22, 2009: HearAtLast CEO Sets Goal to Become Canada's Largest Chain of Hearing Devices

HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) announced yesterday that the Company game plan is to become Canada's largest distribution channel of Hearing Devices and related products and services under its hearing store model co-located within select Wal-Marts in Canada.

http://smallcapvoice.com/blog/8-26-09-audio-interview-with-hearatlast-holdings-inc-otcpk-hral/

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About HearAtLast

HearAtLast Holdings, Inc. is a Nevada corporation that owns and operates its wholly owned subsidiary of hearing stores co-located within select Wal-Mart stores throughout Canada. Their chain of hearing stores specializes in the sale of digital hearing aids and testing services. The Company is the affordable hearing solution for Canadians, combining the most sought after retail space in North America with convenience and location. For more information please visit www.hearatlast.com.

-------------------------------------------

Commonwealth Biotechnologies, Inc. closed at $0.5891 Thursday, trading 30,700 shares.

Company News- October 23, 2009: Commonwealth Biotechnologies, Inc. Receives NASDAQ Notice

Commonwealth Biotechnologies, Inc. (NASDAQ: CBTE) announced earlier today that on July 24, 2009, The NASDAQ Stock Market notified Commonwealth Biotechnologies, Inc. (NASDAQ: CBTE) that CBI was to be delisted from the NASDAQ Capital Market as a result of a failure to comply with NASDAQ Listing Rule 5550(b) due to a failure to maintain minimum stockholders' equity of $2.5 million and a failure to file a Form 8-K affirming compliance with Rule 5550(b).

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About CBI

CBI offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates through: (1) CBI Services, a discovery phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business; and (4) Venturepharm (Asia), a contract research consortium specializing in drug discovery and development, process scale-up, formulation development, cGMP manufacturing and clinical trial management. For more information, visit CBI on the web at www.cbi-biotech.com.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division includes but is not limited to: www.stockprofiler.us; www.associatesfortune.com; www.fastmoneytalk.com; www.markettelegraph.com; www.thewallstreetleader.com; and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market Wire, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes, Hearing Loss, Hearing Aids, Medical Devices, Wal-Mart

CONTACT: Stock Profiler.US e-mail: info@stockprofiler.us WWW: http://www.stockprofiler.us

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Commonwealth Biotechnologies, Inc. Receives NASDAQ Notice - Zibb.com

RICHMOND, Va., Oct 23, 2009 (BUSINESS WIRE) --

On July 24, 2009, The NASDAQ Stock Market notified Commonwealth Biotechnologies, Inc. ("CBI") (NASDAQ: CBTE) that CBI was to be delisted from the NASDAQ Capital Market as a result of a failure to comply with NASDAQ Listing Rule 5550(b) due to a failure to maintain minimum stockholders' equity of $2.5 million and a failure to file a Form 8-K affirming compliance with Rule 5550(b). Subsequently, CBI requested and was granted a hearing to present its plan for regaining compliance under the Rule. That hearing was convened on September 3, 2009. On October 20, 2009, CBI was notified that the Hearing Panel has granted the request of CBI to remain listed on The NASDAQ Stock Market through January 20, 2010, subject to the condition that, on or before January 20, 2010, CBI evidence shareholders' equity of at least $2.5 million or demonstrate compliance with one of the alternative listing criteria of NASDAQ Listing Rule 5550(b).

About CBI

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Specifically, there can be no assurance (i) that CBI will meet all or any of the conditions outlined in the letter; (ii) that CBI will be able to regain and maintain compliance under the Rule; or (iii) that CBI will remain listed on the NASDAQ Capital Market.

SOURCE: Commonwealth Biotechnologies, Inc.

Commonwealth Biotechnologies, Inc. 
Dr. Richard J Freer, COO, 804-648-3820

Commonwealth Biotechnologies, Inc. Receives NASDAQ Notification Regarding Bid Price; Grace Period

RICHMOND, Va., Sep 18, 2009 (BUSINESS WIRE) --

Commonwealth Biotechnologies, Inc. ("CBI" or "Company")) (NASDAQ Capital Market:CBTE) today announced that on September 15, 2009, CBI received a letter from The NASDAQ Stock Market indicating that the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold set forth in NASDAQ Listing Rule 5550(a)(2) for the prior 30 consecutive business days. As such NASDAQ has granted the Company 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement. Should the Company satisfy the criteria for initial listing on The NASDAQ Capital Market (except for bid price) as of March 15, 2010, the Company will be entitled to a second 180-calendar day period, through September 13, 2010, to regain compliance with the minimum bid price requirement. CBI will regain compliance with NASDAQ's minimum bid price requirement if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days during the compliance period. This most recent notice has no impact on the Company's listing at this time.

About CBI

SOURCE: Commonwealth Biotechnologies, Inc.

Commonwealth Biotechnologies, Inc. 
Richard J. Freer, Ph.D., COO, 804-648-3820

Web Sites

Total : 16 View more »

News and Events 2005 - Commonwealth Biotechologies, Inc.

November 29, 2005 Commonwealth Biotechnologies, Inc. to Present at the New York Society of Security Analysts - Company seeks improved analyst coverage.

http://www.cbi-biotech.com/cbi/news_and_events_2005.html

CBTE - Commonwealth Biotechnologies, Inc. Stock Quotes, News, Stock Charts, Report ...

Stock earnings, recommendations and SEC filings for Commonwealth Biotechnologies, Inc.

http://www.quotelinks.com/companies/cbte.html

Pharmacy Choice - Pharmaceutical News - Commonwealth Biotechnologies, Inc. Announces New Contracts

RICHMOND, Va.--(BUSINESS WIRE)--Sept. 12, 2006--Commonwealth Biotechnologies, Inc. (NASDAQ Capital Market: CBTE), today reported receipt of new contract awards totaling approximately $2.35 million.

http://www.pharmacychoice.com/News/article.cfm?Article_ID=36022

St. Louis Business Journal: Commonwealth Biotechnologies Inc company profile

Our forthcoming service has integrated three primary components into company profiles. Discovering relevant information about companies, qualifying it with sales trigger data and connecting you through our patented relationship mapping.

http://stlouis.bizjournals.com/stlouis/gen/Commonwealth_Biotechnologies_Inc_6D93542A36D44634953B42BFF26CE559.html